Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals

BACKGROUND: In Italy, anti-HCV drugs are provided free of charge by the National Health System. Since 2011, three drug regimens including a directly acting antiviral (DAA) are considered the gold standard for HCV treatment. However, these drugs add a significant cost (roughly €26,000) to the combina...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Strazzulla, Alessio, Costa, Chiara, Pisani, Vincenzo, De Maria, Vincenzo, Giancotti, Francesca, Di Salvo, Sebastiano, Parisi, Saverio Giuseppe, Basso, Monica, Franzetti, Marzia Maria, Marascio, Nadia, Liberto, Maria Carla, Barreca, Giorgio Settimo, Lamberti, Angelo Giuseppe, Zicca, Emilia, Postorino, Maria Concetta, Matera, Giovanni, Focà, Alfredo, Torti, Carlo
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160897/
https://ncbi.nlm.nih.gov/pubmed/25236374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-14-S5-S3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars